About Us
What We Do
Our Team
Science
Lead Program
Mechanism of Action
Clinical Trials
Pipeline
Products
Our Products
Patients & Providers
Disease Information
Expanded Access Policy
Publications
IB1000 Series
News
Scientific Presentations
Contact
About Us
What We Do
Our Team
Science
Lead Program
Clinical Trials
Pipeline
Products
Our Products
Patients & Providers
Disease Information
Expanded Access Policy
Publications
IB1000 Series
News
Scientific Presentations
Contact
UNEXPECTED DIFFERENCES IN THE PHARMACOKINETICS OF N-ACETYL DL-LEUCINE ENANTIOMERS AFTER ORAL DOSING AND THEIR CLINICAL RELEVANCE
PLOS ONE, 2020: 15(2)
Privacy Policy
•
Cookies Policy
•
Consumer Product Safety Statement
•
State Compliance
•
Patents
•
©2026 IntraBio. All rights reserved.
